Anaphylm™ (AQST-109)
Severe allergic reactions, including anaphylaxis
Phase 3Late-stage development
Key Facts
Indication
Severe allergic reactions, including anaphylaxis
Phase
Phase 3
Status
Late-stage development
Company
About Aquestive Therapeutics
Aquestive Therapeutics is a publicly traded pharmaceutical company dedicated to advancing patient-centric medicines by simplifying complex drug delivery. With over 2 billion doses of its PharmFilm® products consumed globally and a robust intellectual property portfolio of 200+ patents, the company operates both a proprietary late-stage pipeline and a profitable contract development and manufacturing (CDMO) services business. Its strategic focus is on transmucosal delivery to overcome barriers in existing treatments for CNS disorders and severe allergic reactions, aiming to bring meaningful clinical improvements through its innovative oral film platform.
View full company profile